Case reports [19, 21, 22], and more recently longitudinal clinical trials [24, 25], have shown survival benefits for V600E-positive PXA patients treated with BRAF inhibitors. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.